Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...
Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE®...
A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has ...
Addex Therapeutics a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neu...
Innovent Biologics, Inc. ("Innovent"), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for t...
IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small blood vessels. It is caused by ...
From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-...
Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adop...
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizu...
Pfizer Inc. announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination wi...
Cordis, a global leader in interventional cardiovascular and endovascular technologies, announced new data from two major peripheral studies evaluati...
Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patie...
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
© 2025 Biopharma Boardroom. All Rights Reserved.
